Filtered By:
Specialty: Research
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 130 results found since Jan 2013.

Predicting Which Stroke Patients Will Be Helped — or Harmed — by Clot-Busting Treatment - 5/20/14
Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
Source: Johns Hopkins Medicine News - May 20, 2014 Category: Research Source Type: news

Brain scan checklist set to boost care for stroke survivors
People who suffer a stroke caused by bleeding in the brain could be helped by four simple checks of their brain scans, research suggests. The checks could help spot people at risk of further bleeding so they can be monitored more closely.
Source: Medical Research Council General News - August 15, 2018 Category: Research Source Type: news

Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
CONCLUSIONS: In this contemporary Spanish cohort of NVAF patients on rivaroxaban, patients had many comorbidities, a high thromboembolic risk and a moderate bleeding risk. Overall, rates of stroke and bleeding complications were low and similar to other previous studies. These data suggest that rivaroxaban is effective and safe in routine practice. PMID: 30912682 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - March 27, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Id: 24: benefits and risks of warfarin with and without aspirin in patients with coronary artery disease or cerebrovascular accident: a meta-analysis of randomized controlled trials
Conclusions Use of intermediate intensity warfarin with aspirin reduced the risk of stroke at the price of increased bleeding. Most anticoagulation increased the risk of major bleeding with no effect on mortality. Studies with oral anticoagulants with aspirin for secondary prevention should be considered.
Source: Journal of Investigative Medicine - March 21, 2016 Category: Research Authors: Deshpande, A., Patel, K., Rothberg, M., Pasupuleti, V., Alreja, G., Katzan, I. Tags: Epidemiology/Health Care Outcomes/Quality Improvement/Bioinformatics Source Type: research

Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
CONCLUSIONS: The observed quality of warfarin control in VA EMR suggests room for improvement given the association with elevated risk of adverse clinical outcomes. PMID: 28945114 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 27, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Relationship of Troponin to Incident Atrial Fibrillation Occurrence, Recurrence after Radiofrequency Ablation and Prognosis: A Systematic Review, Meta-Analysis and Meta-Regression.
Conclusions In our systematic review, meta-analysis and meta-regression, TnT was associated with both incident AF occurrence and AF recurrence after RFA, as well as stroke/SE and major bleeding. In contrast, TnI was not associated with incident AF occurrence, AF recurrence after RFA or prognosis (stroke/SE, major bleeding). PMID: 29631448 [PubMed - as supplied by publisher]
Source: Biomarkers - April 12, 2018 Category: Research Tags: Biomarkers Source Type: research

Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.
Conclusion: Elderly patients with NVAF in the U.S. who continued with apixaban treatment had a lower risk of MB-related hospitalization and lower MB- and stroke/SE-related medical costs compared to patients who switched to another OAC. PMID: 31120309 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies.
CONCLUSIONS Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients. For the patients who underwent PCI, prasugrel contributes to lower risk of stent thrombosis. However, prasugrel is associated with significantly higher risk of bleeding. For the patients with active pathological bleeding or a history of stroke and/or TIA, prasugrel should not be recommended. PMID: 25893318 [PubMed - in process]
Source: Medical Science Monitor - April 22, 2015 Category: Research Tags: Med Sci Monit Source Type: research

Safety and Efficacy Analyses of Angioplasty and Stenting for Severe Intracranial Arterial Stenosis: A Single-Center Retrospective Study in China.
CONCLUSIONS A suitable PTAS procedure is safe for patients with severe ICAS, and no significant differences in incidence of recurrent stroke or death were found between PTAS and aggressive medication treatment. PMID: 26517946 [PubMed - as supplied by publisher]
Source: Medical Science Monitor - November 2, 2015 Category: Research Tags: Med Sci Monit Source Type: research

An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
CONCLUSIONS: NVAF patients using different DOACs had different characteristics, including stroke and bleeding risks. Use of rivaroxaban, compared to apixaban was associated with significantly greater risk of bleeding-related readmissions across two database claims analyses. PMID: 26652179 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 18, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
CONCLUSIONS: Our observational data from clinical practice broadly confirm the safety and efficacy results of pivotal randomized controlled trials of apixaban for stroke prevention among NVAF patients. PMID: 29772946 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 19, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease
CONCLUSIONS: Compared to clopidogrel + low dose aspirin, the use of rivaroxaban 2.5 mg twice daily + low dose aspirin reduced the risk of MACE, CV death and stroke including ischemic stroke in patients with or at high risk for chronic CAD and/or PAD. These benefits of rivaroxaban 2.5 mg twice daily + low dose aspirin compared to clopidogrel + low-dose aspirin appear to be achieved without significantly increasing patients' risk of moderate-to-severe including ICH or fatal bleeding.PMID:34641745 | DOI:10.1080/03007995.2021.1991294
Source: Current Medical Research and Opinion - October 13, 2021 Category: Research Authors: Craig I Coleman Akshay A Kharat Brahim Bookhart William L Baker Source Type: research